ReviewThe EMBO journal2008
MHC class II molecules on the move for successful antigen presentation.
Review in The EMBO journal, 2008. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed.
- Role of the Proteasome System in Shaping Cellular Immunological Characteristics and Its Impact in Modulating the Pathogenesis of Immune-Related Diseases.Cells, tissues, organs · 2026Review
- Müller cell glutamine metabolism links photoreceptor and endothelial injury in diabetic retinopathy.Life science alliance · 2026Article
- From immunoinformatics insights to assay development: establishment of a peptide-based indirect elisa for cynomolgus tuberculosis detection.Frontiers in cellular and infection microbiology · 2026Article
- Decoding MHC loss: Molecular mechanisms and implications for immune resistance in cancer.Clinical and translational medicine · 2025Review
- CD70 recruitment to the immunological synapse is dependent on CD20 in B cells.Proceedings of the National Academy of Sciences of the United States of America · 2025Article
- The Atlantic Cod MHC I compartment has the properties needed for cross-presentation in the absence of MHC II.Scientific reports · 2024Article
- Multisystem disorder associated with a pathogenic variant in CLCN7 in the absence of osteopetrosis.Molecular genetics & genomic medicine · 2024Article
- Immune Checkpoint Inhibitor Combined with Antiangiogenic Agent Synergistically Improving the Treatment Efficacy for Solid Tumors.ImmunoTargets and therapy · 2024Review
- Identifying signatures of positive selection in human populations from North Africa.Scientific reports · 2023Article
- Machine learning reveals limited contribution of trans-only encoded variants to the HLA-DQ immunopeptidome.Communications biology · 2023Article
- Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases-Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway.International journal of molecular sciences · 2023Review
- miR-148a regulation interferes in inflammatory cytokine and parasitic load in canine leishmaniasis.PLoS neglected tropical diseases · 2023Article
- Membrane protein trafficking in the anti-tumor immune response: work of endosomal-lysosomal system.Cancer cell international · 2022Review
- Human Pulmonary Tuberculosis: Understanding the Immune Response in the Bronchoalveolar System.Biomolecules · 2022Review
- MHCII Expression on Peripheral Blood Monocytes in Canine Lymphoma: An Impact of Glucocorticoids.Animals : an open access journal from MDPI · 2022Article
- Commensal oral microbiota induces osteoimmunomodulatory effects separate from systemic microbiome in mice.JCI insight · 2022Article
- GILT Expression in Human Melanoma Cells Enhances Generation of Antigenic Peptides for HLA Class II-Mediated Immune Recognition.International journal of molecular sciences · 2022Article
- Efficient Cholesterol Transport in Dendritic Cells Defines Optimal Exogenous Antigen Presentation and Toxoplasma gondii Proliferation.Frontiers in cell and developmental biology · 2022Article
- Maintaining homeostatic control of periodontal bone tissue.Periodontology 2000 · 2021Review
- Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Major histocompatibility complex class II (MHC II) molecules are targeted to endocytic compartments, known as MIIC, by the invariant chain (Ii) that is degraded upon arrival in these compartments. MHC II acquire antigenic fragments from endocytosed proteins for presentation at the cell surface. In a unique and complex series of reactions, MHC II succeed in exchanging a remaining fragment of Ii for other protein fragments in subdomains of MIIC before transport to the cell surface. Here, the mechanisms regulating loading and intracellular trafficking of MHC II are discussed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.